RxDoctor Payments Data

Alexis Gurecki, PA

Physician Assistant · Chesapeake, VANPI 1831329598

Payments from drug & device makers

$8,501in general payments, 2019–2025

Across 346 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Stryker$1K
  • Sanofi$695
  • GSK$683
  • AstraZeneca$637
  • plus $3K from 27 others

What the payments were for

  • Travel & lodging$6528%
  • Food & beverage$7,69791%
  • Education$1522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,501 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$125,013
Medicare patients
625
Services billed
5,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab25$111,515
Dupixent PenDupilumab12$48,176
XhanceFluticasone Propionate18$29,036
Mometasone Furoate106$13,170
Azelastine-FluticasoneAzelastine/Fluticasone72$12,696
Azelastine Hcl298$10,645
Dexlansoprazole DrDexlansoprazole16$7,565
Fluticasone Propionate360$6,812
Ipratropium Bromide86$4,541
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth29$3,842
Montelukast Sodium251$3,051
Budesonide16$3,002
Levocetirizine Dihydrochloride163$2,337
Famotidine84$1,831
Omeprazole110$1,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$1,242$29,03618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →